Group One Trading
MLYS icon

Group One Trading’s Mineralys Therapeutics MLYS Stock Holding History

Group One Trading’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,137
Closed -$219K – 8849
2025
Q2 		$137K Sell
10,137
-2,567
-20% -$37.2K ﹤0.01% 4698
2025
Q1 		$202K Buy
+12,704
New +$146K ﹤0.01% 4003

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Group One Trading's MLYS Position: Q3 2025 in Review

Group One Trading sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 10,137 shares — an estimated $219K sold.

Group One Trading first reported a position in MLYS in Q1 2025 and held it in 2 quarters. The position peaked at $202K in Q1 2025. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • Group One Trading reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Group One Trading sold 10,137 Mineralys Therapeutics shares in Q3 2025, an estimated $219K.
  • Group One Trading first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 2 quarters.
  • Group One Trading's Mineralys Therapeutics position peaked at $202K in Q1 2025.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on Group One Trading's 13F filing for Q3 2025, filed 12 Nov 2025.